Tokyo, Japan

Shigeto Shimmura

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Shigeto Shimmura: Innovator in Corneal Endothelial Substitute Cell Production

Introduction

Shigeto Shimmura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of regenerative medicine, particularly in the production of corneal endothelial substitute cells. With a total of four patents to his name, Shimmura's work is paving the way for advancements in eye care and treatment.

Latest Patents

Shimmura's latest patents include a medium comprising serum replacement, IGF1, STAT3 activator, and adrenal gland hormone without BFGF or ROCK inhibitor for producing corneal endothelial substitute cells from iPS cells. This innovative medium allows for the efficient production of corneal endothelial substitute cells, particularly from induced pluripotent stem (iPS) cells. Additionally, he has developed a rapid tumorigenicity screening system that evaluates the tumorigenicity of test cells by transplanting them into the anterior chamber of an experimental animal. This method enables quick and convenient assessment of tumor formation.

Career Highlights

Throughout his career, Shigeto Shimmura has worked with esteemed institutions such as Keio University and Sumitomo Dainippon Pharma Co., Ltd. His research has focused on enhancing the efficiency of cell production and improving methods for evaluating tumorigenicity, which are crucial for advancing medical treatments.

Collaborations

Shimmura has collaborated with notable colleagues, including Shin Hatou and Kazuo Tsubota. These partnerships have contributed to the development of innovative solutions in the field of regenerative medicine.

Conclusion

Shigeto Shimmura's contributions to the field of regenerative medicine through his patents and collaborations highlight his role as a key innovator. His work continues to influence advancements in the production of corneal endothelial substitute cells and tumorigenicity evaluation methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…